Hwail Pharmaceutical Rises 5.28% Amid COVID-19 (Dexamethasone) Theme Uptrend

On the 6th, the COVID-19 (Dexamethasone) theme showed strength by rising 3.59% compared to the previous day, while Hwail Pharmaceutical, a stock attracting attention as a related company, surged 5.28% compared to the previous day. Hwail Pharmaceutical is known as a specialized manufacturer of pharmaceutical raw materials and others.

[Graph] Major stock price changes in the COVID-19 (Dexamethasone) theme

According to provisional data compiled at 14:28, foreign investors are net selling 6,000 shares of Hwail Pharmaceutical.

[Table] Net trading volume of foreigners and institutions (unit: 10,000 shares)

According to the analysis by Thinkpool Robo Algorithm RASSI, Hwail Pharmaceutical’s quant financial score is 52.91 points, showing higher growth and stability scores than the average of other COVID-19 (Dexamethasone) related stocks, but its quant financial ranking was only 8th out of 15 stocks. On the other hand, Huons ranked first in quant financial ranking with higher growth, stability, and profitability scores compared to other stocks.

[Table] Top financial score stocks within the theme

※ The quant financial score is the result of the Robo Algorithm’s analysis based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, and other factors.

※ This article was generated in real-time by an article auto-generation algorithm jointly developed by Asia Economy and the financial AI specialist Thinkpool.